Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

    Virtual Booth

    Contact Supplier

    Coral

    Virtual Booth

    Contact Supplier

    ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

    Virtual Booth

    Contact Supplier

    Menu

    Koate DVI

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 6Advate

    02 4Kogenate

    03 6Kogenate/Kovaltry/ Jivi

    04 1KogenateTM

    05 3Recombinate

    06 1Refacto AF

    07 8Refacto AF/Xyntha

    08 1Refacto Af/Xyntha

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Refacto AF/Xyntha

    Antihemophilic Factor (Recombinant)

    arrow
    World Drug Safety EU
    Not Confirmed

    Brand Name : Refacto AF/Xyntha

    U.S.A
    arrow
    World Drug Safety EU
    Not Confirmed

    Pfizer Inc.

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2019 Revenue in Millions : 426

    2018 Revenue in Millions : 514

    Growth (%) : -17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Kogenate/Kovaltry/ Jivi

    Antihemophilic Factor (Recombinant)

    arrow
    World Drug Safety EU
    Not Confirmed

    Brand Name : Kogenate/Kovaltry/ Jivi

    Germany
    arrow
    World Drug Safety EU
    Not Confirmed

    Bayer

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2020 Revenue in Millions : 1,029

    2019 Revenue in Millions : 1,067

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Advate

    Antihemophilic Factor (Recombinant)

    arrow
    World Drug Safety EU
    Not Confirmed

    Brand Name : Advate

    Japan
    arrow
    World Drug Safety EU
    Not Confirmed

    Takeda

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Hematology

    Currency : USD

    2019 Revenue in Millions : 1,443

    2018 Revenue in Millions : 0

    Growth (%) : N/A

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Kogenate/Kovaltry/ Jivi

    Antihemophilic Factor (Recombinant)

    arrow
    World Drug Safety EU
    Not Confirmed

    Brand Name : Kogenate/Kovaltry/ Jivi

    Germany
    arrow
    World Drug Safety EU
    Not Confirmed

    Bayer

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2021 Revenue in Millions : 906

    2020 Revenue in Millions : 1,029

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Advate

    Antihemophilic Factor (Recombinant)

    arrow
    World Drug Safety EU
    Not Confirmed

    Brand Name : Advate

    Japan
    arrow
    World Drug Safety EU
    Not Confirmed

    Takeda

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 1,253

    2019 Revenue in Millions : 1,473

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Refacto AF/Xyntha

    Antihemophilic Factor (Recombinant)

    arrow
    World Drug Safety EU
    Not Confirmed

    Brand Name : Refacto AF/Xyntha

    U.S.A
    arrow
    World Drug Safety EU
    Not Confirmed

    Pfizer Inc.

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2020 Revenue in Millions : 370

    2019 Revenue in Millions : 426

    Growth (%) : -13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Advate

    Antihemophilic Factor (Recombinant)

    arrow
    World Drug Safety EU
    Not Confirmed

    Brand Name : Advate

    Japan
    arrow
    World Drug Safety EU
    Not Confirmed

    Takeda

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 1,019

    2020 Revenue in Millions : 1,201

    Growth (%) : -9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Refacto AF/Xyntha

    Antihemophilic Factor (Recombinant)

    arrow
    World Drug Safety EU
    Not Confirmed

    Brand Name : Refacto AF/Xyntha

    U.S.A
    arrow
    World Drug Safety EU
    Not Confirmed

    Pfizer Inc.

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2021 Revenue in Millions : 304

    2020 Revenue in Millions : 370

    Growth (%) : -18

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Kogenate/Kovaltry/ Jivi

    Antihemophilic Factor (Recombinant)

    arrow
    World Drug Safety EU
    Not Confirmed

    Brand Name : Kogenate/Kovaltry/ Jivi

    Germany
    arrow
    World Drug Safety EU
    Not Confirmed

    Bayer

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 889

    2021 Revenue in Millions : 906

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Refacto AF/Xyntha

    Antihemophilic Factor (Recombinant)

    arrow
    World Drug Safety EU
    Not Confirmed

    Brand Name : Refacto AF/Xyntha

    U.S.A
    arrow
    World Drug Safety EU
    Not Confirmed

    Pfizer Inc.

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2022 Revenue in Millions : 239

    2021 Revenue in Millions : 304

    Growth (%) : -21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF